We want to create and live with HWA an “Ubuntu”, which means we can success, only if we are, cooperate together. Ubuntu is an old African hospitality and business tradition which defines how to success based in a synergy and “win-win” position.

The new partnership is a complete new step for Media-Soft Inc. because we will expand now with our partner from Johannesburg across the complete African Commonwealth part.

South Africa is continuously developing and today represents the cultural, social and business center of the African continent. We are proud and excited that we can be one of the first specialized Pharma CRM providers for such an important market.

About HWA Marketing and Sales Consulting

HWA Marketing and Sales consulting is a synonym for pharma consulting SFE, coaching and education services in South Africa. HWA Marketing and Sales has built his brand name based on trust, excellence and new innovative trends. From 2010 HWA Marketing and Sales Consulting has also the exclusive distribution rights for Sales Vision Pharma CRM in South Africa.

About Media-Soft

Media-Soft Inc. is one of the leaders in the Pharma CRM sector. The mission and focus of the company is to be a pharmacentric oriented company. The main product Sales Vision Pharma CRM, today improves marketing and sales processes of more than 28 pharma companies worldwide. Sales Vision Pharma CRM is one of the most innovative solutions because it’s available on all existing platforms like the native iPhone/iPad Pharma CRM app.

Pharmacentric since 1996 is our value.

Media-Soft would like to welcome the 28th pharma client worldwide, L’Oreal Adria who will implement Sales Vision Pharma CRM, the PC version called Sales Vision Pharma 9 in five countries.

We are very proud to have such a respectful new partner, who is a standard in the cosmetic industry but from our point of view also a pharmaceutical company because they are social responsible, innovative driven and of course the care about people.

L’Oreal is a complete new challenge for Media-Soft because together we need to improve the SFE and daily work of the sales and marketing department. L’Oreal has showed that they know to recognize all crucial trends and needs of a modern sales force team by implementing Sales Vision Pharma CRM.

About L’Oreal

The L’Oréal Group is the world’s largest cosmetics and beauty company. With its registered office in Paris and head office in the Paris suburb of Clichy, Hauts-de-Seine, France, it has developed activities in the field of cosmetics. Concentrating on hair color, skin care, sun protection, make-up, perfumes and hair care, the company is active in the dermatological and pharmaceutical fields and is the top nanotechnology patent-holder in the United States. L’Oreal was founded in 1909 and today employees around the globe 67.000 people.

About Media-Soft

Media-Soft Inc. is one of the leaders in the Pharma CRM sector. The mission and focus of the company is to be a pharmacentric oriented company. The main product Sales Vision Pharma CRM, today improves marketing and sales processes of more than 28 pharma companies worldwide. Sales Vision Pharma CRM is one of the most innovative solutions because it’s available on all existing platforms like the native iPhone/iPad Pharma CRM app.   

Pharmacentric since 1996 is our value.

Alkaloid Russia has implemented Sales Vision Win version for their medical reps to increase the sales force effectiveness, integrate pharma marketing/sales activities and manage the customer relationship management. The big sales force from Alkaloid Russia now will have better conditions to plan/organize their visits and to have a better flow of marketing/sales processes on the dynamic Russian market.

“This was a very important project for us, to establish the partnership with Alkaloid Russia because now we have integrated almost all Alkaloid global representatives. We will finally integrate all global Alkaloid representatives during this year. After that the cooperation just starts, says Damir Safaric, CEO of Media-Soft.”

Sales Vision has been present on the Russian market now for more than 6 years and the number of users is continuously increasing.

About Alkaloid

ALKALOID AD is a company that for seven decades now is in the business of manufacturing drugs, processing botanical raw material, manufacturing cosmetics and chemical products.
Alkaloid AD Skopje is a joint stock company made of two profit centers: Pharmaceuticals and Chemicals, Cosmetics & Botanicals; we have two daughter companies: Alkaloid Coatings and Alkaloid CONS as well as 12 subsidiaries abroad (in Serbia, Montenegro, Kosovo, in Albania, Bosnia and Herzegovina, Croatia, Slovenia, Switzerland, Bulgaria, Romania, in the Russian Federation, Ukraine and USA). The presence of Alkaloid is on a global level which indicates the global vision of the company with a great brand portfolio and synonym for pharma excellence.  
We are a company with around 1100 employees; with dominant part of the capital owned by private shareholders, out of which 13% are foreign investors.

Nycomed’s performance was driven by strong growth of Key Products and in most emerging markets. This overall positive performance could not fully offset the expected negative impact of pantoprazole’s patent expiry in Europe. Daxas® (roflumilast) is advancing well: Nycomed received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of Daxas® in the European Union. With Merck & Co., Inc. (MSD) a co-promotion agreement for five European countries and Canada has been signed.

Nycomed also made significant advancement in its partnerships: With the FDA approval of TachoSil®, Baxter International will be able to market this surgical patch in the United States. In Russia/CIS, an agreement with GE Healthcare to form a joint venture for the local sales, marketing and distribution of GE Healthcare’s medical diagnostic contrast agents has been announced.

A jury in the U.S. District Court for the District of New Jersey held that the US pantoprazole (Protonix®) patent is not invalid. Nycomed and its US partner Pfizer Inc. are pleased with the jury’s findings and announced that as soon as the decision is final the companies will be seeking the full measure of their damages.

Håkan Björklund, CEO Nycomed, commented on the company’s results: “We saw a very satisfactory performance in the first quarter of 2010 confirming our direction. Both Key Products and the emerging markets are developing well.

With a positive opinion from the CHMP, we have cleared an important hurdle of the European approval process for Daxas. To further utilize the potential of Daxas, we have signed a co-promotion agreement with Merck for several European countries and Canada. All of this confirms our belief in the future of this product. We were disappointed with the outcome from the recent FDA Advisory Committee meeting that reviewed Daxas. However, we remain optimistic that concerns expressed by the Committee and the FDA can be satisfactorily resolved.

For 2010, we will see the full effect of pantoprazole’s loss of exclusivity. In some markets we anticipate pressure on pharmaceuticals prices from authorities. We do expect further growth of our Key Products and in emerging markets and are preparing the launch of Daxas.”

Financial background
Adjusted EBITDA and EBITDA are key figures used in order to have a more comprehensive analysis of our operating performance and of our ability to service our debt. EBITDA means net income adjusted for net financial terms, income taxes, depreciation of tangible assets and amortisation of intangible assets. Adjusted EBITDA is EBITDA adjusted for unusual or non-recurring items not related to the future and ongoing business. For the first quarter 2010 the difference between EBITDA and adjusted EBITDA mainly comprises integration, projects and restructuring costs.

About Nycomed
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company’s growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

Source: http://www.pharmanews.eu/

Bayer Schering Pharma AG, Germany, will establish a U.S. Innovation Center in San Francisco, Calif. with the goal to expand its global research network and build its specialty pharmaceutical pipeline.

The model introduces a newly formed “Science Hub” for innovation sourcing in the U.S. creating collaborations with academic research scientists and small biotech firms to realize product development and commercialization of new therapies through partnerships with Bayer. The U.S. Innovation Center also will house Bayer scientists who drive the company’s strong hematology research program focused on coagulation factors and the discovery of novel biologic drug candidates.

“Through our newest innovation center, U.S. academic research institutions and young biopharmaceutical firms will work closely with Bayer scientists and leverage our experience in bringing novel discoveries to market. Working together, we have the potential to create significant benefits for patients,” said Professor Andreas Busch, Head of Global Drug Discovery for Bayer Schering Pharma. “Mission Bay is a hotbed of innovation in the U.S. and key to our decision to co-locate our researchers in this life sciences community. We expect this new focus on U.S. research collaboration to enhance Bayer’s pipeline which features a successful combination of internal excellence with highly partnered approaches in research and development and commercialization.”

By locating the U.S. Innovation Center in Mission Bay, Bayer’s scientists will be in the heart of a growing biomedical research community and working in state-of-the-art labs which will occupy 49,000 square feet of leased lab and administrative space. Also research scientists working in targeted areas such as cardiology, oncology, women’s healthcare and diagnostic imaging will be rotating through this site.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover, manufacture and market products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.

About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at

Source: http://www.worldpharmanews.com/content/view/1228/30/

Source: http://www.worldpharmanews.com/

GlaxoSmithKlineMexico implements Sales Vision Anywhere as for sales force effectiveness of the marketing and sales processes. Sales Vision Pharma CRM on different platforms now becomes a new important and famous user.

“We know that Sales Vision is now a brand and synonym for pharma excellence and this fact many international pharmaceutical companies can identify as an proof of quality and experience that we have accumulated from 1996, Damir Safaric, CEO”

GlaxoSmithKline is a British pharmaceutical, biological, and healthcare company. GSK is the world’s fourth largest pharmaceutical company by revenue ; and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines.

Media-Soft is annoucing new Sales Vision Pharma 9 CRM, successor of successfully Sales Vision Win 2006. 

Sales Vision Pharma 9 brings a brand new user experience based on design, user-friendly interface and flexibility. The Sales Force Effectiveness has become a new improvement tool for pharma marketing and sales efforts.

Also we have integrated many improvements for a better daily work and developed new modules for the pharma needs and processes. The system is certificated with the Windows 7 logo what means it is fully compatible with the new Windows 7.

From new modules that are available we underline Dashboards, iTargeting, Sales Plan and Sample management. Also one great improvement that we have made is based on parallel use of platforms, which means that you can mix different platforms of Sales Vision as you sales force tool.

For any information’s please contact our team.

” We have once again proven that with a synergy of Sales Vision and the Mexican partners we can provide a high quality software solution for such strategic pharmaceutical company like Roche., says Damir Safaric, CEO“

About Roche

Roche plays a pioneering role in healthcare. As an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, we contribute on a broad range of fronts to improving people’s health and quality of life. Roche is providing the first products that are tailored to the needs of specific patient groups. Our mission today and tomorrow is to create added value in healthcare by focusing on our expertise in diagnostics and pharmaceuticals.

Serbian pharmaceutical company Bonifar implements the new Sales Vision Pharma 9 for sales force effectiveness. Media-Soft is pleased to welcome a new partner who is ambitious and who knows the strategic value of Sales Vision Pharma CRM.